Cost-benefit analysis of interferon therapy in children with chronic active hepatitis B

Journal of Pediatric Gastroenterology and Nutrition

Volumn 24, Issue 1, 1997, Pages 25-32

  Louis Jacques, Otto ^a   Olson, Allan D ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b F6854 CS Mott/0200 ^*  (United States)

Author keywords

Interferon; Children; Chronic active hepatitis B; Cost benefit analysis

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHRONIC ACTIVE HEPATITIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL;

ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COST-BENEFIT ANALYSIS; DRUG COSTS; HEPATITIS B; HEPATITIS, CHRONIC; HUMANS; INTERFERON-ALPHA;

EID: 0030982845     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-199701000-00008     Document Type: Article

References (71)

1. Maynard JE. Hepatitis B: global importance and need for control. Vaccine 1990;8(suppl):18-20S.
2. McQuillan GM, Townsend TR, Fields HA, Carrole M, Leahy M, Polk BF. Seroepidemiology of hepatitis B virus infection in the United States, 1976 to 1980. Am J Med 1989;87(suppl 3A):5-10S.
3. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: Evolving epidemiology and implications for control. Semin Liver Dis 1991;11: 84-92.
4. MMWR. Protection against viral hepatitis: recommendations of the Immunization Practices Advisory Committee. MMWR Morb Mortal Wkly Rep 1990;39(RR-2):1-26.
5. Centers for Disease Control. Hepatitis surveillance. Report no. 52. Atlanta: Public Health Service, 1989.
6. Committee on Infectious Diseases. Universal hepatitis B immunization. Pediatrics 1992;89:795-9.
7. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323: 295-301.
8. Perez V, Tanno H, Villamil F, Fay O. Recombinant interferon alpha-2b following prednisone withdrawal in the treatment of chronic type B hepatitis. J Hepatol 1990;11:S113-7.
9. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993;119:312-23.
10. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991;114:629-34.
11. Di Bisceglie AM, Fong TL, Fried MW, et al. A randomized, controlled trial of recombinant α-interferon therapy for chronic hepatitis B. Am J Gastroenterol 1993;88:1887-92.
12. Perrillo RP, Brunt EM. Hepatic histologic and immunohistochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B e antigen and hepatitis B surface antigen. Ann Intern Med 1991;115:113-5.
13. Lai CL, Lok ASF, Lin HJ, Wu PC, Yeoh EK, Yeung CY. Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg carrier children. Lancet 1987;2:877-80.
14. Lai CL, Lin HJ, Lau JYN, et al. Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children. Q J Med 1991;78:155-63.
15. 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. Hepatology 1994;20:287-90.
16. Burczynska B, Madalinski K, Pawlowska J, et al. The value of quantitative measurement of HBeAg and HBsAg before interferon-α treatment of chronic hepatitis B in children. J Hepatol 1994;21:1097-102.
17. Ruiz-Moreno M, Jimenez J, Porres JC, Bartolome J, Moreno A, Carreno V. A controlled trial of recombinant interferon-alpha in Caucasian children with chronic hepatitis B. Digestion 1990;45: 26-33.
18. Ruiz-Moreno M, Rua MJ, Molina J, et al. Prospective, randomized controlled trial of interferon-alpha in children with chronic hepatitis B. Hepatology 1991;13:1035-9.
19. Sokal EM, Wirth S, Goyens P, Depreterre A, Cornu C. Interferon alpha-2b therapy in children with chronic hepatitis B. Gut 1993; 34(suppl):S87-90.
20. Utili R, Sagnelli E, Galanti B, et al. Prolonged treatment of children with chronic hepatitis B with recombinant alpha 2a-interferon: a controlled, randomized study. Am J Gastroenterol 1991;86:327-30.
21. Utili R, Sagnelli E, Gaeta GB, et al. Treatment of chronic hepatitis B in children with prednisone followed by alpha-interferon: a controlled randomized study. J Hepatol 1994;20:163-7.
22. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-α2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122:664-75.
23. Garcia de Ancos JL, Roberts JA, Dusheiko GM. An economic evaluation of the costs of α-interferon treatment of chronic active hepatitis due to hepatitis B or C virus. J Hepatol 1990;11(suppl 1):S11-8.
24. Dudley FJ, Scheurer PJ, Sherlock S. Natural history of hepatitis-associated antigen-positive chronic liver disease. Lancet 1972;2: 1388-93.
25. Bloom SB, Hillman AL, Fendrick M, Schwartz JS. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Intern Med 1993;118:298-306.
26. Beasley RP. Hepatitis B virus as the etiologic agent in hepatocellular carcinoma: epidemiologic considerations. Hepatology 1982; 2:21-6S.
27. Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. Hepatology 1995;21:77-82.
28. De Jongh FE, Janssen HLA, De Man RA, Hop WCJ, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-5.
29. D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986;31:468-75.
30. Liaw Y-F, Lin D-Y, Chen T-J, Chu C-M. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989;9:235-41.
31. Lo K-J, Tong MJ, Chien M-C, et al. The natural course of hepatitis B surface antigen-positive chronic active hepatitis in Taiwan. J Infect Dis 1982;146:205-10.
32. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. NIH Conference: hepatocellular carcinoma. Ann Intern Med 1988;108:390-401.
33. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin 1993;43:7-26.
34. Shinozaki T, Saito K, Shiraki K. HBsAg-positive giant cell hepatitis and cirrhosis in a 10-month-old infant. Arch Dis Child 1981; 56:64-6.
35. Bortolotti F, Calzia R, Cadrobbi P, et al. Liver cirrhosis associated with chronic hepatitis B virus infection in childhood. J Pediatr 1986;108:224-7.
36. Shapiro CN. Epidemiology of hepatitis B. Pediatr Infect Dis J 1993;12:433-7.
37. Liaw Y-F, Tai D-I, Chu C-M, Chen T-J. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988;8:493-6.
38. Weissberg JI, Andres LL, Smith CI, et al. Survival in chronic hepatitis B. Ann Intern Med 1984;101:613-6.
39. Wu TC, Tong MJ, Hwang B, Lee S-D, Hu MM. Primary hepatocellular carcinoma and hepatitis B infection during childhood. Hepatology 1987;7:46-8.
40. Hsu H-C, Wu MZ, Chang MH, Su IJ, Chen DS. Childhood hepatocellular carcinoma develops exclusively in hepatitis B surface antigen carriers in three decades in Taiwan. J Hepatol 1987;5: 260-7.
41. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus with hepatitis immune globulin and hepatitis B vaccine. Lancet 1983;2:1099-102.
42. Conjeevaram HS, Di Bisceglie AM. Management of chronic viral hepatitis in children. J Pediatr Gastroenterol Nutr 1995;20:365-75.
43. Crivellaro C, Cadrobbi P, Perilongo G, Rossetti F, Pontisso P, Bortolotti F. Chronic type B hepatitis and primary hepatocellular carcinoma in children. Eur J Pediatr 1991;150:685.
44. Chang MH, Hsu HY, Ni YH. Significance of spontaneous hepatitis B e seroconversion in children [Abstract]. J Pediatr Gastroenterol Nutr 1995;21:353.
45. Hsieh C-C, Tzonou A, Zavitsanos X, Kaklamani E, Lan S-J, Trichopoulos D. Age at first establishment of chronic hepatitis B virus infection and hepatocellular carcinoma risk: a birth order study. Am J Epidemiol 1992;136:1115-21.
46. National Center for Health Statistics. Vital Statistics of the United States, 1989. Volume II. Mortality, part A. Washington: Public Health Service, 1993.
47. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA 1995;274:1201-8.
48. Liaw Y-F, Tai D-I, Chu C-M, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. Gastroenterology 1986;90:263-7.
49. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991;13:619-26.
50. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-7.
51. Lykavieris P, Fabre M, Yvart J, Alvarez F. HBV infection in pediatric liver transplantation. J Pediatr Gastroenterol Nutr 1993; 16:321-7.
52. Perrillo RP, Mason AL. Hepatitis B and liver transplantation: problems and promises [Editorial]. N Engl J Med 1993;329:1885-7.
53. Smith CS, Paauw DS. Hepatocellular carcinoma, identifying and screening populations at increased risk. Postgrad Med 1993;94: 71-4.
54. Sherman M, Pelketian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995;22:432-8.
55. Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325:675-80.
56. Hurie MB, Mast EE, Davis JP. Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees. Pediatrics 1992;89:269-73.
57. Davis LG, Weber DJ, Lemon SM. Horizontal transmission of hepatitis B virus. Lancet 1989;1:889-93.
58. Christenson B. Epidemiological aspects of the transmission of hepatitis B by HBsAg-positive adopted children. Scand J Infect Dis 1986;18:105-9.
59. Bayraktar Y, Uzunalimoglu B, Arslan S, Koseglu T, Kayhan B, Telatar H. Effects of recombinant alpha interferon on chronic active hepatitis B: preliminary results. Gut 1993;34:5101.
60. Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991:294-8.
61. De Groote J, Fevery J, Lepoutre L. Long-term follow-up of chronic active hepatitis of moderate severity. Gut 1978;19:510-3.
62. Moreno-Otero R, Garcia-Monzon C. Garcia-Sanchez A, Buey Garcia L, Pajares JM, Di Bisceglie AM. Development of cirrhosis after chronic type B hepatitis: a clinicopathologic and follow-up study of 46 HBeAg-positive asymptomatic patients. Am J Gastroenterol 1991;86:560-4.
63. Narkewicz MR, Smith D, Silvennan A, Vierling J, Sokol RJ. Clearance of chronic hepatitis B virus infection in young children after alpha Interferon treatment. J Pediatr 1995;127:815-8.
64. Lok ASF, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese hepatitis B. Hepatology 1988;8:1130-3.
65. Lok ASF, Lai CL, Wu PC, Lau JYN, Leung EKY, Wong LSK. Treatment of chronic hepatitis B with Interferon: experience in Asian patients. Semin Liver Dis 1989;9:249-53.
66. Roberts SD, Maxwell DR, Gross TL. Cost-effective care of end-stage renal disease: a billion dollar question. Ann Intern Med 1980;92(part 1):243-8.
67. Kinosian BP, Eisenberg JM. Cutting into cholesterol: cost-effective alternatives for treating hypercholesterolemia. JAMA 1988;259:2249-54.
68. Arii S, Tobe T. Epidemiology of liver cancer in Japan and the world. Gann Monograph Cancer Res 1991;38:17-26.
69. Nerenstone SR, Friedman MA, Ihde DC. Primary liver cancer. In: Moossa AR, Schimpff SC, Robson MC, eds. Comprehensive textbook of oncology. Baltimore: Williams & Wilkins, 1991:948-57.
70. Beasley RP, Shiao I, Wu T, Hwang L. Hepatoma in an HBsAg carrier seven years after perinatal infection. J Pediatr 1982;101: 83-4.
71. Harvey VJ, Woodfield DG, Probert JC. Maternal transmission of hepatocellular carcinoma. Cancer 1984;54:1360-3.